...seeking accelerated approval for the therapy. Interprotein deploys AI tech to identify COVID-19 compounds Osaka-based Interprotein Corp....

...Ipsen and Interprotein partnered to develop therapeutic peptides to treat endocrine diseases, including Cushing’s disease. Ipsen...
...Cushing’s disease. Ipsen will have an exclusive option to license candidates developed during the partnership. Interprotein...
...for publication. Interprotein uses two structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. Interprotein Corp....

...Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine...
...Cushing's disease. Ipsen will have an exclusive option to license candidates developed during the partnership. Interprotein...
...did not disclose candidates or targets in the deal and did not respond to inquiries. Interprotein...

...18%) of 273 compounds tested were identified as hit compounds. The compounds were designed using Interprotein's...
...RaQualia. RaQualia is eligible for worldwide, exclusive rights of any products resulting from the partnership. Interprotein...
...lead generation "in the near future." RaQualia declined to disclose details (see BioCentury, Feb. 4). Interprotein Corp....

...The companies partnered to design and develop protein-protein interaction inhibitors for undisclosed indications. Interprotein will use...
...undisclosed target from Takeda, which will conduct drug discovery research based on the design from Interprotein...
...partnered in December 2011 to develop a small molecule protein-protein interaction using INTENDD. Last November, Interprotein...

...mid-year. RaQualia Pharma Inc. (JASDAQ:4579) gained ¥70 (11%) to ¥720 on Friday after partnering with Interprotein Corp....
...pain. RaQualia is eligible for exclusive, worldwide rights to any products resulting from the deal. Interprotein...

...protein-protein interaction inhibitors for undisclosed pain indications. RaQualia will be responsible for discovering candidates, while Interprotein...
...inhibitors. RaQualia is eligible for worldwide, exclusive rights of any products resulting from the partnership. Interprotein...
...payment and research milestones. The companies could not be reached for details. In December 2011, Interprotein...

...RaQualia Pharma Inc. (JASDAQ:4579) and Interprotein Corp. (Osaka, Japan) partnered to discover and develop protein-protein interaction inhibitors...
...interaction inhibitors for undisclosed pain indications. The companies said RaQualia will identify candidate compounds, and Interprotein...
...candidates. RaQualia is eligible for worldwide, exclusive rights to any products resulting from the deal. Interprotein...

...after about 11% of the compounds tested were found to bind to the target protein. Interprotein...
...design are "well below 11%." The companies partnered last December to develop the compounds using Interprotein's...
...Design (INTENDD) technology. The companies could not be reached for comment (see BioCentury, Jan. 9). Interprotein Corp....

...protein-protein interaction using Interprotein's INTENDD (Interprotein's Engine for New Drug Design). Details were not disclosed. Interprotein Corp....